<DOC>
	<DOCNO>NCT02306811</DOCNO>
	<brief_summary>Primary Objective : To assess long-term safety vatelizumab MS patient Secondary Objective : To assess long-term efficacy vatelizumab</brief_summary>
	<brief_title>Efficacy Safety Vatelizumab Patients Who Completed Treatment Study DRI13839</brief_title>
	<detailed_description>The maximum study duration per patient 192 week , include Treatment Period 96 week Post-treatment Safety Follow-up Period 96 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion criterion : Patients complete 12week treatment period DRI13839 . Exclusion criterion : Any clinically significant ongoing adverse event , laboratory abnormality DRI13839 per Investigator judgment would adversely affect patient 's participation longterm extension study . Confirmed platelet count lower limit normal time DRI13839 . Pregnancy breastfeeding . Other protocol define exclusion criterion may apply . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>